Non-surgical treatment of erectile dysfunction.
Authors survey the conservative treatment possibilities of erectile dysfunction. With the increase in interest, they estimate the new oral- and intracavernosal drugs, giving a review of their experiences with the treatment. A perspective prognosis is given of the important role of NO (nitric oxide) donors and PHD (phosphodiesterase) inhibitor drugs in the field of conservative therapy, while intracavernosal and intraurethral prostaglandin therapies are still important ingredients in the therapeutic arsenal, as is hormone substitution in indicated cases.
Papp
G
G
Clinic of Urology Center of Andrology, Semmelweis Medical School, Budapest, Hungary.
Kopa
Z
Z
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001046:Aphrodisiacs / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D018377:Neurotransmitter Agents / Q000819:agonists; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000008:administration & dosage / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D001046:Aphrodisiacs; D006728:Hormones; D018377:Neurotransmitter Agents; D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D014665:Vasodilator Agents